Medtronic's Second-Quarter Financial Outlook: Cardiovascular Segment Set to Drive Growth Momentum

Medtronic (MDT) is preparing to unveil its second-quarter fiscal 2026 financial results on November 18 at market open. The medical technology powerhouse demonstrated solid performance in its most recent quarter, delivering earnings per share of $1.26—outpacing the Zacks Consensus Estimate by 2.44%. This marks the fourth consecutive quarter in which MDT has surpassed analyst expectations, with an average surprise margin of 2.20%.

Second-Quarter Consensus Expectations

For the current reporting period, Wall Street consensus projects MDT revenues of $8.86 billion, representing a 5.4% increase year-over-year. Analysts anticipate earnings per share to reach $1.31, translating to a 4% year-over-year expansion. The earnings guidance has remained stable throughout the past 60 days, with no significant revisions.

Performance Drivers Across Key Business Units

Cardiovascular: The Growth Engine

The cardiovascular portfolio stands positioned to deliver robust growth, underpinned by diversified strength across multiple product categories. Cardiac Ablation Solutions continues to demonstrate accelerating momentum, with PulseSelect and Affera Sphere-9 pulsed field ablation systems gaining significant adoption in both domestic and international markets. Expanded hiring efforts and supply chain optimization are facilitating market penetration in new healthcare systems while deepening relationships with existing partners.

Structural heart therapies also reflect positive trajectory. The Evolut FX+ TAVR device has shown expanding market acceptance, particularly in Japan and other international territories. Market dynamics have shifted favorably for MDT following a competitor’s exit, enabling revenue concentration improvement. Premium cardiac rhythm products—including AURORA EV-ICD, Micra leadless pacemakers, and conduction system pacing solutions—continue reinforcing the division’s performance foundation.

Consensus models forecast Cardiovascular revenue growth of 8.4% year-over-year, marking the segment’s strongest contribution to overall MDT expansion.

Neuroscience: Modulation and Surgical Innovation

The neuroscience division encompasses multiple growth pathways. Cranial and spinal technologies benefit from rising adoption of the AiBLE spine technology platform, while core spine and neurosurgery offerings maintain steady contribution. The Inceptiv closed-loop spinal cord stimulator has captured growing U.S. market share within the neuromodulation category, particularly in pain management applications.

Brain modulation therapeutics gain traction through BrainSense Adaptive DBS technology deployment among Parkinson’s patients. A significant milestone occurred in September when the FDA approved the Altaviva device for minimally invasive tibial neuromodulation therapy targeting urge urinary incontinence—expanding the addressable market further.

First-quarter results for specialty therapies reflected temporary headwinds from tender pricing pressures in China and recalls affecting neurovascular products. Management guidance suggests material improvement during the second quarter. The Zacks Consensus Estimate projects 1.5% year-over-year neuroscience revenue growth.

Medical Surgical: Advancing Procedural Solutions

MDT’s medical surgical portfolio is expected to capitalize on sustained demand for LigaSure vessel sealing technology, driving market share expansion within advanced energy applications. ProGrip self-gripping polyester mesh continues gaining surgical adoption, while electrosurgery and esophageal product lines maintain momentum consistent with prior-quarter trajectory.

The Touch Surgery AI-powered platform represents an emerging growth vector, potentially expanding MDT’s digital footprint within procedural environments. Revenue guidance for this segment anticipates 5.4% year-over-year expansion.

Diabetes: Strategic Transformation and Clinical Expansion

The diabetes unit demonstrates compelling growth characteristics fueled by strong international uptake of the MiniMed 780G automated insulin delivery system and Simplera Sync continuous glucose monitoring sensor. Guardian 4 CGM sensors and Extended Infusion Sets continue experiencing favorable market reception.

Clinical validation strengthened during the period—the FDA cleared SmartGuard algorithm compatibility with Abbott’s Instinct sensor for type 1 diabetes, while MiniMed 780G gained approval for adults 18+ with insulin-dependent type 2 diabetes. These regulatory advances are anticipated to support top-line expansion.

Beyond product performance, MDT is advancing the planned spin-off of its diabetes business into an independent public entity named MiniMed. This strategic repositioning enables the broader MDT portfolio to concentrate on high-margin expansion categories, particularly pulsed field ablation and renal denervation therapies. Consensus estimates indicate 9.2% year-over-year diabetes segment revenue growth.

Investment Framework Assessment

MDT currently holds a Zacks Rank #3 (Hold) classification with an Earnings ESP of 0.00%. Historical patterns indicate that stocks combining favorable rank ratings with positive Earnings ESP tend to exceed expectations; however, this combination is not present in MDT’s current profile.

Alternative Opportunities in Medtech

For investors seeking comparable exposure with more favorable earnings surprise probabilities, consider these alternatives:

Veeva Systems (VEEV) demonstrates +0.26% Earnings ESP and Zacks Rank #2 status ahead of November 20 third-quarter results. The company has exceeded expectations in four consecutive quarters (9.71% average surprise), with projected 11.43% third-quarter EPS growth.

Alpha Cognition Inc. (ACOG) shows +9.30% Earnings ESP and Rank #3 status for November 13 third-quarter results. Trailing four-quarter average beat stands at 21.74%, with 27.7% estimated 2025 earnings growth versus industry average of 13%.

Ascendis Pharma (ASND) displays +27.25% Earnings ESP ahead of November 12 third-quarter disclosure. Four-quarter average surprise reaches 11.15%, with third-quarter loss-per-share metrics expected to improve 78.3% year-over-year.